EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment

This study plans to learn if certain markers found during electroencephalogram (EEG) analysis could predict fenfluramine responsiveness to give clinicians greater insight into the effectiveness of fenfluramine in people with Lennox Gastaut Syndrome (LGS).

Study Overview

• Status: Enrolling by invitation
• Conditions: Lennox Gastaut Syndrome (LGS)
• Intervention / Treatment: Drug: fenfluramine HCl

• Study Type: Observational
• Enrollment (Estimated): 20

Contacts and Locations

Study Locations

• United States
  • Illinois
    • Chicago, Illinois, United States, 60637
      • University of Chicago

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients at University of Chicago who have been diagnosed with Lennox-Gastaut Syndrome (LGS)

Description

Inclusion criteria:

• Children and adults aged 2 to 35 years
• Have a confirmed diagnosis of Lennox-Gastaut Syndrome (LGS), validated by the Epilepsy Study Consortium
• Documented seizure onset at age 11 years or younger, accompanied by multiple seizure types, specifically including tonic seizures and atonic or tonicatonic seizures.
• Participants must exhibit a stable seizure baseline for at least 4 weeks prior to enrollment, with documented frequency of two or more drop seizures per week, characterized as generalized tonic-clonic (GTC), secondary GTC (focal to bilateral tonic-clonic seizures), tonic, atonic, or combined tonic-atonic seizures.
• Participants must exhibit abnormal cognitive development and a medical history consistent with electroencephalographic (EEG) findings demonstrating abnormal background activity characterized by a slow spike-andwave pattern at a frequency of less than 2.5 Hz.
• Participants must have a clearly documented etiology of LGS falling into one of the following categories: structural, genetic, metabolic, infectious, immune or unknown.
• Participants must have had a valid baseline EEG that reflects their clinical state during a stable seizure period and must have been conducted within 6 months prior to study enrollment.
• Participants must be currently receiving fenfluramine as part of their clinical management regimen. Fenfluramine dosing must follow established LGS-specific dosing guidelines, initiated at 0.1 mg/kg administered orally twice daily, with weekly dose titration based on tolerability and clinical response until reaching the recommended maintenance dose of 0.35 mg/kg orally twice daily, not exceeding a total daily dose of 26 mg.
• At the time of enrollment, participants must have been on a stable antiseizure medication (ASM) regimen for at least 30 days, defined as receiving between one and four concomitant ASMs without any recent medication changes, aside from the addition of fenfluramine. To ensure accurate baseline EEG assessments, participants must have a documented EEG recorded within 6 months (±2 months) prior to initiation of fenfluramine treatment.
• Caregivers or legal guardians must provide informed consent, and participant assent will be obtained when developmentally appropriate according to ethical standards.

Exclusion Criteria:

• Patients have been diagnosed with any progressive neurodegenerative disorders, as these conditions could confound the interpretation of fenfluramine's clinical efficacy and safety profile.
• Individuals with a documented history of fenfluramine use prior to obtaining baseline EEG will be excluded to ensure the baseline EEG data accurately represent the pre-treatment neurophysiological state.
• Participants who have incomplete medical records, inadequate EEG documentation, or insufficient diagnostic workup confirming LGS diagnosis.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of participants who have concordance between electroencephalogram (EEG) changes and clinical responsiveness in patients diagnosed with Lennox-Gastaut Syndrome (LGS) undergoing treatment with fenfluramine after 6 months.	from EEG prior to fenfluarmine initiation to follow up EEG 6 months after

Secondary Outcome Measures

Outcome Measure	Time Frame
Number of participants whose specific EEG biomarkers are predicative of clinical responsiveness to fenfluramine treatment before, during, and after fenfluramine treatment	from EEG prior to fenfluarmine initiation to follow up EEG 6 months after
Change from baseline differences of longitudinal EEG dynamics before and during fenfluramine therapy, including changes in background activity, paroxysmal fast activity, epileptiform discharges, and sleep architecture.	from EEG prior to fenfluarmine initiation to follow up EEG 6 months after
Number of clinical responders and non-responders to fenfluramine treatment measured by differences in quantitative EEG variables after 6 months	from EEG prior to fenfluramine initiation to follow up EEG 6 months after
Change from baseline in quality of life scores on the Ped-QL epilepsy or QL-Epilepsy after 6 months	from prior to EEG initiation to 6 months after

Collaborators and Investigators

• Sponsor: University of Chicago
• Collaborators: UCB Pharma

Study record dates

Study Major Dates

• Study Start (Estimated): April 1, 2026
• Primary Completion (Estimated): December 1, 2027
• Study Completion (Estimated): April 1, 2028

Study Registration Dates

• First Submitted: April 21, 2026
• First Submitted That Met QC Criteria: April 21, 2026
• First Posted (Actual): April 29, 2026

Study Record Updates

• Last Update Posted (Actual): May 7, 2026
• Last Update Submitted That Met QC Criteria: May 1, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: fenfluramine; Lennox Gastaut Syndrome (LGS)
• Additional Relevant MeSH Terms: Epileptic Syndromes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Epilepsy; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Lennox Gastaut Syndrome; Organic Chemicals; Amines; Phenethylamines; Ethylamines; Fenfluramine
• Other Study ID Numbers: IRB25-1092

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: This study will be conducted at a single site and data sharing is not necessary.

Drug and device information, study documents

• Studies a U.S. FDA-regulated device product: No